TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03791879
Drug: Caudal dexamedatomidine analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg.
Study: NCT04165837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
Study: NCT01374425
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 400 mg/m\^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
Study: NCT01374425
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 850 or 1000 mg/m\^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
Study: NCT00226356
Drug: Supplements of L-methionine, betaine and folate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02551185
Drug: ACY-241
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01525043
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg BID for the first 2 weeks
Study: NCT02449187
Drug: JLP-1310, Fasted followed by fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition.
Study: NCT02449187
Drug: JLP-1310, Fed followed by fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition.
Study: NCT01525043
Drug: Synera patch for 12hrs/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
Study: NCT01525043
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg bid
Study: NCT00629928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00954447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, identical to Linagliptin tablet
Study: NCT03690778
Drug: Metformin and Rosuvastatin seperately
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of Metformin and Rosuvastatin seperately
Study: NCT03690778
Drug: JLP-1310
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of JLP-1310
Study: NCT03420105
Drug: Hormonotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant hormone therapy
Study: NCT00678704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet prior to intercourse on demand
Study: NCT01126073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
Study: NCT02988908
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14
Study: NCT02873156
Drug: E2027 matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
Study: NCT00506623
Drug: Capecitabine, Irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01202695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT04542681
Drug: Placebo - 1st Cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single SQ injection of placebo/normal saline
Study: NCT04542681
Drug: MANP - 1st Cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
Study: NCT04542681
Drug: MANP - 2nd Cycle
Normalized name: CEPHALOSPORIN 2ND GENERATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
Study: NCT01203345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An equal volume of 5 percent albumin solution
Study: NCT00992550
Drug: Cigarette
Normalized name: CIGARETTE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00992550
Drug: Hookah
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01340456
Drug: Rifampicin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
Study: NCT00004466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01997164
Drug: REGN910-3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01997164
Drug: REGN910
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01137890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules administered in split doses at 22:00 and 09:00.
Study: NCT00003888
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03896633
Drug: Azopt 1%
Normalized name: Azopt 1% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azopt 1%, RLD
Study: NCT01006395
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: yearly infusion
Study: NCT01006395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: yearly infusion
Study: NCT03419494
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
Study: NCT03419494
Drug: DNR
Normalized name: Do Not Resuscitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
Study: NCT00318617
Drug: GW510516X
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03498716
Drug: Dose-dense Doxorubicin or dose-dense Epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses
Study: NCT03498716
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
Study: NCT04770207
Drug: Injection of drug-eluting microspheres with multiple drugs into solid tumors
Normalized name: microspheres of human albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
Study: NCT00934921
Drug: Zofran®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 8 mg ODT
Study: NCT02406651
Drug: Systemic Corticosteroids
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
Study: NCT01815125
Drug: PLacebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00916227
Drug: ARRY-614, p38/Tie2 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Study: NCT03467113
Drug: ZX008 0.2 to 0.8 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
Study: NCT02783833
Drug: MMV390048 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02248571
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered as combined therapy with Bevacizumab
Study: NCT03616821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
Study: NCT04233515
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical visit to a physician to assess stroke and bleeding risk and to possibly initiate OAC therapy or refer for left atrial appendage occlusion
Study: NCT03429140
Drug: Gel-One
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
Study: NCT00437099
Drug: Omacor®
Approvals — FDA: no, EMA: no, PMDA: no
Description: arm 1: Omacor 1680 Arm 2: Omacor 3360
Study: NCT00437099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01017614
Drug: Iron Sulphate
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg daily
Study: NCT02103465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal patch
Study: NCT02114645
Drug: 4 mg oral estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estrofem is given twice a day
Study: NCT04145596
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
Study: NCT00431964
Drug: azithromycin 250 mg tablets
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs
Study: NCT00431964
Drug: placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: * One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs
Study: NCT02108288
Drug: OPC-1085EL ophthalmic solution
Normalized name: Opcon-A Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04450732
Drug: GQ1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-HER2 antibody drug conjugate
Study: NCT01985789
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03509025
Drug: Jointstem
Approvals — FDA: no, EMA: no, PMDA: no
Description: JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
Study: NCT00665834
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 20 mg from day 0 to (maximum) day 6
Study: NCT00665834
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 20 mg from day 0 to (maximum) day 6
Study: NCT00665834
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 20 mg from discharge until the end of the study
Study: NCT01722240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01516372
Drug: GEn Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GEn Tablets
Study: NCT01518920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution
Study: NCT03514784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin
Study: NCT02738151
Drug: Non-insulin anti-diabetic treatment
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
Study: NCT00119418
Drug: TU 025 Keishi Bukuryo Gan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00153660
Drug: Celecoxib(drug)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 100 mg bd
Study: NCT00153660
Drug: Naproxen(drug)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500 mg bd
Study: NCT04138056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
Study: NCT01928524
Drug: DOS2w Dose level 2A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Study: NCT01483560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years duration
Study: NCT02578901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
Study: NCT00567554
Drug: epirubicin - cyclophosphamide / docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00567554
Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03949517
Drug: 68-Ga RM2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioactive agent
Study: NCT03949517
Drug: 68-Ga PSMA11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioactive agent
Study: NCT01429688
Drug: Anplag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
Study: NCT00133445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
Study: NCT00608062
Drug: Transdermal estradiol patch
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
Study: NCT00608062
Drug: Transdermal placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
Study: NCT00746811
Drug: P-OM3
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 grams/day - 4 one gram capsules
Study: NCT00746811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 grams/day - 4 one gram capsules
Study: NCT04016714
Drug: V114
Normalized name: Pneumococcal 15-valent Conjugate Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
Study: NCT04016714
Drug: Prevenar 13™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
Study: NCT04016714
Drug: Vaxelis™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 0.5 mL single dose
Study: NCT04016714
Drug: M-M-R®II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous 0.5 mL single dose
Study: NCT04016714
Drug: VARIVAX™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous 0.5 mL single dose
Study: NCT01928524
Drug: DOS3w Dose level 3B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Study: NCT00867139
Drug: TCAD
Normalized name: Tricyclic Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
Study: NCT03253107
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin
Study: NCT00923910
Drug: Endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified lipopolysaccharide prepared from E.Coli 0:113
Study: NCT00833521
Drug: AMBIEN® 10 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10 mg
Study: NCT01590173
Drug: Prednisolone and Heparin during COH for IVF
Normalized name: prednisolone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
Study: NCT00923910
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-medication
Study: NCT01448642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
Study: NCT00425620
Drug: SinuNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavage
Study: NCT03158831
Drug: Placebo-Controlled Graded Drug Challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
Study: NCT00016354
Drug: benzoylphenylurea
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00320099
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg as iv bolus every 6 hours for 7 days
Study: NCT00320099
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: hydrocortisone 50mg q6 for 7 days
Study: NCT02625779
Drug: Valproate and Creatine-containing Drug
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02740270
Drug: GWN323
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02740270
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04046939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice daily oral dosing for up to 12 weeks
Study: NCT01498861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a tablet with no drug in it
Study: NCT03553238
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
Study: NCT02987738
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: two administrations in the evening and 12 hours later
Study: NCT02247128
Drug: OAC + clopicogrel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00542178
Drug: Hypoglycemic Agents
Normalized name: HYPOGLYCEMIC AGENTS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
Study: NCT00542178
Drug: Standard glycemia control
Approvals — FDA: no, EMA: no, PMDA: no
Description: A strategy of glycemia drugs for HbA1c 7% - 7.9%
Study: NCT00542178
Drug: Intensive BP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
Study: NCT00542178
Drug: Standard BP control
Approvals — FDA: no, EMA: no, PMDA: no
Description: A strategy of BP drugs for SBP less than 140 mm Hg
Study: NCT00542178
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20-40 mg/d
Study: NCT00542178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo